Core Concepts
Amivantamab offers ongoing benefit in EGFRm NSCLC.
Abstract
The content discusses the benefits of combining the bispecific antibody amivantamab with chemotherapy in the treatment of epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC). The analysis includes follow-up data from two phase 3 trials, PAPILLON and MARIPOSA-2, and an exploratory analysis of a third trial, MARIPOSA-1. Key highlights include the extended progression-free survival, reduced risk for second progression or death, and the impact on brain progression. The content also addresses the management of adverse events and the implications for patient outcomes.
Stats
Patients receiving the combination in the first line had a longer progression-free survival of 11.4 months vs 5.7 with chemotherapy alone.
The combination reduced the risk for second disease progression or death by 51%.
Amivantamab plus chemotherapy was associated with a 52% improvement in progression-free survival vs chemotherapy alone.
The time to treatment discontinuation was significantly longer with the combination.
The combination led to a better median progression-free survival compared to chemotherapy alone.
Quotes
"The combination is a new standard of care among patients with EGFR-mutant advanced non–small cell lung cancer after disease progression on osimertinib." - Ryan D. Gentzler, MD
"Dose interruptions were a meaningful way of managing adverse events without compromising outcomes." - Maria Rosario Garcia Campelo, MD
"There's a clear benefit to amivantamab for patients with classic EGFR mutations." - Zofia Piotrowska, MD